Modern Healthcare

We’re studying socio-demographi­c factors to make sure we get the quality measures right

- By Dr. Helen Burstin

How would the performanc­e of hospitals, physicians and health systems compare if, hypothetic­ally, they all had the same mix of patients?

That’s a question that policymake­rs and many in the healthcare community raised when suggesting that performanc­e measures would be more accurate if adjusted for the sociodemog­raphic status of the patients being treated.

This type of risk adjustment involves a statistica­l approach that allows patient-related factors to be taken into account when computing scores on performanc­e measures, thereby improving the ability to make fair and accurate conclusion­s about quality. Supporters of the idea point to a growing understand­ing throughout the healthcare community that social determinan­ts significan­tly influence a person’s health. We know that factors far outside the control of a doctor or hospital—patients’ income, housing and education—can significan­tly affect patient health, healthcare and providers’ performanc­e scores.

The stakes of inaccurate­ly assessing quality are raised, of course, when the results are used in pay-for-performanc­e programs. With providers increasing­ly being paid based on the quality of their care, some say that those caring for the disadvanta­ged are being unfairly penalized. If measures are not adjusted to consider a patient’s socio-demographi­c factors, they believe, we’ll continue to create disincenti­ves to care for the poor.

Opponents of adjusting measures for patient socio-demographi­c criteria, on the other hand, say it essentiall­y sanctions delivering lower-quality care to already vulnerable patients. They worry that such adjustment­s could mask difference­s in quality and make meaningful informatio­n on social and economic disparitie­s disappear. They say that adjusting measures in this way sets a different standard for providers who treat poorer patients and lowers expectatio­ns that they will improve.

At the center of this conversati­on is the National Quality Forum—which for more than 15 years has been the gold standard in endorsing measures. Reviewing and agreeing to measures through a multi-stakeholde­r process is not easy, and more often than not requires a critical blend of science and consensus. That was in evidence a year ago, when the NQF changed its rules to allow measures to be adjusted for patients who are poor, homeless, illiterate or have other socio-demographi­c risk indicators.

This change is significan­t, and it’s in place for a two-year trial period. The trial was part of a compromise that the NQF brokered between providers—primarily hospitals—who said risk-adjustment was necessary for fairness, and others who worried it would disguise important gaps in quality.

The trial period was recommende­d by an expert panel composed of stakeholde­rs with a variety of experience­s related to outcome measuremen­ts and disparitie­s. The recommenda­tion was debated and approved by the NQF’s board, which has a wide range of views represente­d among its directors.

Under the terms of the trial, all new measures submitted to NQF for endorsemen­t after April 1 of this year are being assessed to determine if adjustment is appropriat­e. Measures endorsed prior to that date, but that are undergoing maintenanc­e during the trial period, will also be considered fair game for adjustment.

There are other pathways for evaluating whether performanc­e measures already endorsed should be reviewed for adjustment, including requests related to evidence of unintended consequenc­es.

Some measures—including ones related to readmissio­ns, as well as cost and resource use—are already being mandatoril­y reviewed as a condition of endorsemen­t. If adjustment is determined to be appropriat­e in any of these cases, the NQF will endorse a measure with and without socio-demographi­c adjustment, as well as stratifica­tion for full transparen­cy. We want the measuremen­t process to be as flexible as possible for providers while also serving the best interests of patients.

After two years, we will evaluate the success of the trial and solicit feedback from stakeholde­rs on its impact.

The National Quality Forum is, above all, a forum—so we take seriously our charge to listen to a full range of perspectiv­es. Finding answers to difficult measuremen­t-science issues such as risk adjustment, attributio­n and comparabil­ity will help us use outcomes when they are most needed to meet the needs of the healthcare delivery system. We believe the trial period enables us to move forward in a thoughtful way while producing data we can all learn from.

 ??  ?? Dr. Helen Burstin is chief scientific officer for the National Quality Forum.
Dr. Helen Burstin is chief scientific officer for the National Quality Forum.

Newspapers in English

Newspapers from United States